GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mainz Biomed NV (FRA:4TO) » Definitions » Institutional Ownership

Mainz Biomed NV (FRA:4TO) Institutional Ownership : 0.01% (As of Apr. 12, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Mainz Biomed NV Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Mainz Biomed NV's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Mainz Biomed NV's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Mainz Biomed NV's Float Percentage Of Total Shares Outstanding is 96.14%.


Mainz Biomed NV Institutional Ownership Historical Data

The historical data trend for Mainz Biomed NV's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mainz Biomed NV Institutional Ownership Chart

Mainz Biomed NV Historical Data

The historical data trend for Mainz Biomed NV can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 0.06 0.06 0.06 0.06 0.01 0.01 0.01 0.01 0.01 0.01

Mainz Biomed NV Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Mainz Biomed NV Business Description

Traded in Other Exchanges
Address
Robert Koch Strasse 5, Sirius Gutenberg Park, Mainz, RP, DEU, 55129
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Mainz Biomed NV Headlines

No Headlines